Baillie Gifford & Co. Sells 573,810 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Baillie Gifford & Co. reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 35.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,063,266 shares of the company's stock after selling 573,810 shares during the quarter. Baillie Gifford & Co. owned about 2.29% of Pacira BioSciences worth $35,875,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Financial Freedom LLC purchased a new position in shares of Pacira BioSciences in the 4th quarter worth about $33,000. ICA Group Wealth Management LLC purchased a new stake in Pacira BioSciences during the fourth quarter worth approximately $35,000. China Universal Asset Management Co. Ltd. grew its stake in Pacira BioSciences by 96.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company's stock worth $36,000 after buying an additional 583 shares during the period. Neo Ivy Capital Management acquired a new stake in shares of Pacira BioSciences in the second quarter worth $44,000. Finally, Nisa Investment Advisors LLC raised its stake in shares of Pacira BioSciences by 310.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company's stock valued at $61,000 after acquiring an additional 1,514 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. TheStreet raised shares of Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Monday, March 4th. Royal Bank of Canada cut their price objective on shares of Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. Needham & Company LLC restated a "buy" rating and set a $45.00 target price on shares of Pacira BioSciences in a research note on Tuesday. Finally, JPMorgan Chase & Co. assumed coverage on Pacira BioSciences in a research note on Thursday, March 7th. They issued an "overweight" rating and a $45.00 price target on the stock. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pacira BioSciences has a consensus rating of "Buy" and a consensus price target of $49.50.

Pacira BioSciences Stock Down 1.7 %

Pacira BioSciences stock traded down $0.47 during midday trading on Thursday, hitting $27.36. The stock had a trading volume of 323,567 shares, compared to its average volume of 493,467. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average price of $29.49 and a 200 day moving average price of $29.98. Pacira BioSciences, Inc. has a 12 month low of $25.93 and a 12 month high of $48.60. The stock has a market cap of $1.27 billion, a P/E ratio of 33.79 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, meeting analysts' consensus estimates of $0.71. The business had revenue of $181.24 million during the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. Research analysts predict that Pacira BioSciences, Inc. will post 2.18 EPS for the current year.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the firm's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares of the company's stock, valued at $4,165,193.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now owns 22,127 shares in the company, valued at approximately $677,086.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary W. Pace sold 1,066 shares of Pacira BioSciences stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares of the company's stock, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.